US FDA advisers overwhelmingly back authorizing Pfizer Covid-19 vaccine
The decision comes after a 23-member panel met to determine whether the drug's benefits outweigh the risks
The decision comes after a 23-member panel met to determine whether the drug's benefits outweigh the risks